AXON Neuroscience, an industry leading, clinical stage biotech at the forefront of treatment and prevention of Alzheimer’s disease, has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine to slow down the progression of Alzheimer’s Disease. The Phase II ADAMANT trial was designed as a randomized, double-blinded, placebo- controlled trial in mild Alzheimer’s Disease. The primary objective was safety, with secondary objectives to evaluate immunogenicity, efficacy on clinical outcomes and key biomarkers. Axon studied AADvac1 on 196 patients in eight European countries over 24 months, in order to prove the concept of disease modifying effect of the vaccine and to inform the design of future confirmatory studies.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
Biosimilar
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
Diagnostics
Digital Health
Drug Discovery
EpiVax'
FDA
FDA approval
funding
fundraising
HIV
Immunogenicity
Immunotherapies
INVO Bioscience
Licensing
M&A
medical device
microbiome
Neuro
next-gen sequencing
NGS
PathAI
pathology
Pepticom
peptides
pharma
PierianDx
RNA
robots
Shape Therapeutics
skin
software
SurgiMab
Therapeutics
therapies
USA
VIrology
Virus